Evolent Health, Inc. (NYSE:EVH) Shares Purchased by Forest Hill Capital LLC

Forest Hill Capital LLC boosted its stake in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 223.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 144,750 shares of the technology company's stock after buying an additional 100,000 shares during the quarter. Evolent Health makes up approximately 1.3% of Forest Hill Capital LLC's portfolio, making the stock its 25th largest holding. Forest Hill Capital LLC owned about 0.12% of Evolent Health worth $1,628,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Evolent Health by 2.4% in the 4th quarter. Vanguard Group Inc. now owns 11,171,199 shares of the technology company's stock worth $125,676,000 after purchasing an additional 259,781 shares during the period. Engaged Capital LLC raised its holdings in shares of Evolent Health by 35.5% during the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company's stock valued at $60,804,000 after acquiring an additional 1,415,300 shares in the last quarter. Cadian Capital Management LP purchased a new stake in Evolent Health in the fourth quarter worth about $58,781,000. Dimensional Fund Advisors LP boosted its stake in Evolent Health by 19.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,897,443 shares of the technology company's stock worth $32,595,000 after acquiring an additional 466,225 shares in the last quarter. Finally, Boston Partners grew its stake in shares of Evolent Health by 92.0% in the fourth quarter. Boston Partners now owns 2,444,006 shares of the technology company's stock worth $27,097,000 after acquiring an additional 1,171,304 shares during the last quarter.

Evolent Health Price Performance

Shares of NYSE:EVH traded down $0.11 on Thursday, reaching $8.84. The company's stock had a trading volume of 743,916 shares, compared to its average volume of 2,395,613. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a 50-day simple moving average of $9.62 and a 200 day simple moving average of $11.34. The company has a market cap of $1.03 billion, a P/E ratio of -10.79 and a beta of 1.04. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.02). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The firm had revenue of $483.65 million for the quarter, compared to the consensus estimate of $460.15 million. During the same period in the previous year, the company posted $0.34 EPS. Evolent Health's quarterly revenue was down 24.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EVH shares. Stephens reduced their price target on shares of Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a research note on Tuesday, January 21st. UBS Group increased their target price on shares of Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Canaccord Genuity Group dropped their price target on shares of Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Monday, April 28th. Finally, Oppenheimer decreased their price objective on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $17.79.

Insider Transactions at Evolent Health

In other news, Director Brendan B. Springstubb bought 5,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average cost of $8.75 per share, with a total value of $43,750.00. Following the acquisition, the director now directly owns 11,842 shares in the company, valued at $103,617.50. This trade represents a 73.08% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Diane Holder acquired 2,735 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of $9.33 per share, with a total value of $25,517.55. Following the completion of the transaction, the director now directly owns 70,584 shares of the company's stock, valued at approximately $658,548.72. This represents a 4.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 74,000 shares of company stock valued at $666,315. Company insiders own 1.40% of the company's stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.